Sangamo Therapeutics (SGMOQ) Net Income towards Common Stockholders (2010 - 2025)

Sangamo Therapeutics has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$37.4 million in Q4 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 59.94% year-over-year to -$37.4 million in Q4 2025; TTM through Dec 2025 was -$122.9 million, a 23.89% decrease from a year earlier, with the FY2025 full-year figure at -$122.9 million, down 25.52% from the prior year.
• Net Income towards Common Stockholders was -$37.4 million for Q4 2025 at Sangamo Therapeutics, down from -$34.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $21.1 million in Q1 2023, with the low at -$114.5 million in Q2 2023.
• Average Net Income towards Common Stockholders over 5 years is -$42.5 million, with a median of -$43.6 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders sank 3062.33% in 2021, then surged 148.01% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$37.5 million in 2021, then plunged by 38.63% to -$51.9 million in 2022, then retreated by 16.08% to -$60.3 million in 2023, then jumped by 61.2% to -$23.4 million in 2024, then plunged by 59.94% to -$37.4 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$37.4 million (Q4 2025), -$34.9 million (Q3 2025), and -$20.0 million (Q2 2025), per Business Quant data.